AMP-activated protein kinase modulators: A patent review (2006 - 2010)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 7, 2011, Pages 983-1005

  Yun, Hee ^a   Ha, Joohun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

AMPK; AMPK modulators; cancer; metabolic disorders; pharmaceutical compounds

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENOSINE PHOSPHATE; BARBINERVIC ACID; BENZIMIDAZOLE DERIVATIVE; BIGUANIDE DERIVATIVE; CISPLATIN; CONJUGATED LINOLEIC ACID; D 942; DOXORUBICIN; ETOPOSIDE; FURAN 2 CARBOXYLIC ACID DERIVATIVE; GLABRIDIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; IMIDAZOLE DERIVATIVE; METADOXINE; METFORMIN; NECTANDRIN; NOOKATONE; OBOVATOL; PHENFORMIN; QUINAZOLINE DERIVATIVE; RESVERATROL; SCOPARONE; THIAZOLIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE; TRITERPENOID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER PREVENTION; DRUG DESIGN; DRUG IDENTIFICATION; DRUG STRUCTURE; ENZYME ACTIVATION; FEEDING; GENE EXPRESSION; GENE TARGETING; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPOTHALAMUS; IMPAIRED GLUCOSE TOLERANCE; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC REGULATION; NONHUMAN; OBESITY; REVIEW; WEIGHT GAIN;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; METABOLIC DISEASES; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS;

EID: 79959389619     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.577069     Document Type: Review

References (148)

1. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 2008;32(Suppl 4):S7-12
2. Hawley SA, Pan DA, Mustard KJ, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005;2(1):9-19 (Pubitemid 43239821)
3. Woods A, Dickerson K, Heath R, et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005;2(1):21-33 (Pubitemid 43239822)
4. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003;2(4):28
5. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003;13(22):2004-8 (Pubitemid 37425212)
6. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007;47:185-210.
7. Dossus L, Kaaks R. Nutrition, metabolic factors and cancer risk. Best Pract Res Clin Endocrinol Metab 2008;22(4):551-71
8. Hardie DG, Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 1997;246(2):259-73 (Pubitemid 27232500)
9. Abbud W, Habinowski S, Zhang JZ, et al. Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport. Arch Biochem Biophys 2000;380(2):347-52 (Pubitemid 30659105)
10. Zheng D, MacLean PS, Pohnert SC, et al. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol 2001;91(3):1073-83 (Pubitemid 32803899)
11. Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol 1999;87(5):1990-5
12. Suwa M, Egashira T, Nakano H, et al. Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J Appl Physiol 2006;101(6):1685-92 (Pubitemid 44904490)
13. Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 2000;10(20):1247-55
14. Bergeron R, Previs SF, Cline GW, et al. Effect of 5-aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001;50(5):1076-82 (Pubitemid 32374538)
15. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108(8):1167-74. (Pubitemid 32995375)
16. Foretz M, Ancellin N, Andreelli F, et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005;54(5):1331-9 (Pubitemid 40586661)
17. Andreelli F, Foretz M, Knauf C, et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006;147(5):2432-41
18. Lochhead PA, Salt IP, Walker KS, et al. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 2000;49(6):896-903 (Pubitemid 30349410)
19. Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006;3(6):403-16. (Pubitemid 43811782)
20. Mayr BM, Canettieri G, Montminy MR. Distinct effects of cAMP and mitogenic signals on CREB-binding protein recruitment impart specificity to target gene activation via CREB. Proc Natl Acad Sci USA 2001;98(19):10936-41 (Pubitemid 32878722)
21. Nakae J, Cao Y, Oki M, et al. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes 2008;57(3):563-76
22. Hirota K, Sakamaki J, Ishida J, et al. A combination of HNF-4 and Foxo1 is required for reciprocal transcriptional regulation of glucokinase and glucose-6-phosphatase genes in response to fasting and feeding. J Biol Chem 2008;283(47):32432-41
23. Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005;437(7062):1109-11
24. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120(7):2355-69.
25. Carling D, Hardie DG. The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta 1989;1012(1):81-6
26. Jorgensen SB, Nielsen JN, Birk JB, et al. The alpha2-5AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes 2004;53(12):3074-81 (Pubitemid 39564481)
27. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106(2):171-6 (Pubitemid 30483118)
28. Henin N, Vincent MF, Gruber HE, et al. Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 1995;9(7):541-6
29. Muoio DM, Seefeld K, Witters LA, et al. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J 1999;338(Pt 3):783-91 (Pubitemid 29140087)
30. Kawaguchi T, Osatomi K, Yamashita H, et al. Mechanism for fatty acid 'sparing effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 2002;277(6):3829-35 (Pubitemid 34968632)
31. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 1996;10(9):1096-107 (Pubitemid 26152851)
32. Corton JM, Gillespie JG, Hawley SA, et al. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995;229(2):558-65
33. Daval M, Diot-Dupuy F, Bazin R, et al. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem 2005;280(26):25250-7 (Pubitemid 40934619)
34. Gauthier MS, Miyoshi H, Souza SC, et al. AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. J Biol Chem 2008;283(24):16514-24
35. Song XM, Fiedler M, Galuska D, et al. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 2002;45(1):56-65 (Pubitemid 34118543)
36. Buhl ES, Jessen N, Schmitz O, et al. Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta- D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. Diabetes 2001;50(1):12-7 (Pubitemid 32047974)
37. Iglesias MA, Ye JM, Frangioudakis G, et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002;51(10):2886-94
38. Park CE, Kim MJ, Lee JH, et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 2007;39(2):222-9
39. Hardie DG. The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci 2004;117(Pt 23):5479-87. (Pubitemid 40012195)
40. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277(28):25226-32 (Pubitemid 34951829)
41. Hawley SA, Gadalla AE, Olsen GS, et al. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002;51(8):2420-5 (Pubitemid 34827390)
42. Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010;11(6):554-65.
43. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310(5754):1642-6 (Pubitemid 41780780)
44. Industry Academy Cooperation Foundation Chosun University. Composition for preventing or treating obesity-related diseases mediated by the activation of AMPK and including 2,5-bis-aryl-3,4-dimethylterahydrofuran lignans as active ingredients. WO2010140734; 2010
45. Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Use of compounds extracted from MOMORDICA CHARANTIA L. in the manufacture of medicaments for prevention and treatment of diabetes and obesity. EP2255816 2010
46. IND Academic Coop. AMPK activators from the leaves of DIOSPYROS KAKI and compositions for treatment and prevention of obesity or diabetes mellitus containing the same as an active ingredient. KR2010054653; 2010
47. TG Biotech Co. Ltd. Composition for the treatment of diabetes and metabolic syndrome containing obovatol and its synthesized derivatives. US20100125103; 2010
48. Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. WO2010051206; 2010
49. Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. WO2010051176; 2010
50. Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. WO2010047982; 2010
51. Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. WO2010036613; 2010
52. Ohta Y, Bacus SS, Shell SA. Heart protection by administering an AMP-activated protein kinase activator. WO2010036910; 2010
53. Dr. REDDYs Laboratories Ltd. Modulation of endogenous AMPK levels for the treatment of obesity. WO2009019600; 2009
54. Rigel Pharmaceuticals, Inc. N-substitutedheterocycloalkyloxybenzamide compounds and methods of use. WO2008083124; 2008
55. Korea Research Institute of Chemical Technology. Furan-2-carboxylic acid derivatives and process for the preparation thereof. WO2008016278; 2008
56. Kosaka T, Okuyama R, Sun W, et al. Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry. Anal Chem 2005;77(7):2050-5 (Pubitemid 40463820)
57. MD BioAlpha Co., Ltd. Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin. WO2007058480; 2007
58. Kao Corp. AMPK activating agent. US20070054965; 2007
59. Rault S, Lancelot JC, Kopp M, et al. Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same. US20060069117; 2006
60. SK Chemicals, Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity. WO06071095; 2006
61. Sanders MJ, Grondin PO, Hegarty BD, et al. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 2007;403(1):139-48 (Pubitemid 46569875)
62. Hemminki A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cell Mol Life Sci 1999;55(5):735-50 (Pubitemid 29257624)
63. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009;196(1):65-80.
64. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115(5):577-90 (Pubitemid 37506046)
65. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30(2):214-26 (Pubitemid 351626684)
66. Hippert MM, OToole PS, Thorburn A. Autophagy in cancer: good, bad, or both? Cancer Res 2006;66(19):9349-51
67. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005;6(6):439-48 (Pubitemid 40780556)
68. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007;7(12):961-7 (Pubitemid 350165856)
69. Meijer AJ, Codogno P. AMP-activated protein kinase and autophagy. Autophagy 2007;3(3):238-40 (Pubitemid 46752685)
70. Papandreou I, Lim AL, Laderoute K, et al. Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death Differ 2008;15(10):1572-81
71. Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007;9(2):218-24. (Pubitemid 46420865)
72. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8(4):253-67 (Pubitemid 351430863)
73. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351(6326):453-6 (Pubitemid 21896613)
74. Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ 2006;13(6):1027-36
75. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4(10):793-805 (Pubitemid 39331151)
76. Feng Z, Hu W, de Stanchina E, et al. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 2007;67(7):3043-53 (Pubitemid 46724841)
77. Lee CH, Inoki K, Karbowniczek M, et al. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J 2007;26(23):4812-23 (Pubitemid 350191300)
78. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008;134(3):451-60
79. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002;3(5):298-302 (Pubitemid 34546447)
80. Lewitt MS. Stimulation of IGF-binding protein-1 secretion by AMP-activated protein kinase. Biochem Biophys Res Commun 2001;282(5):1126-31 (Pubitemid 32912842)
81. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330(7503):1304-5 (Pubitemid 40813563)
82. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120(5):1263-70 (Pubitemid 32246678)
83. Anisimov VN, Egormin PA, Bershtein LM, et al. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 2005;139(6):721-3 (Pubitemid 41372239)
84. Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005;40(8-9):685-93 (Pubitemid 41265819)
85. Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412(2):211-21 (Pubitemid 351758227)
86. Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant EGFR or KRAS genotype. WO2010114922; 2010
87. BETAGENON AB. Compounds useful as inhibitors as AMPK. WO2010086613; 2010
88. Saitoh M, Nagai K, Nakagawa K, et al. Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relevant to activation of AMP-activated protein kinase. Biochem Pharmacol 2004;67(10):2005-11 (Pubitemid 38591388)
89. Kefas BA, Cai Y, Ling Z, et al. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 2003;30(2):151-61 (Pubitemid 36592509)
90. Kefas BA, Cai Y, Kerckhofs K, et al. Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem Pharmacol 2004;68(3):409-16 (Pubitemid 38887423)
91. Kefas BA, Heimberg H, Vaulont S, et al. AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia 2003;46(2):250-4 (Pubitemid 36343889)
92. Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010;70(6):2465-75.
93. Kato K, Ogura T, Kishimoto A, et al. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 2002;21(39):6082-90
94. Yun H, Kim HS, Lee S, et al. AMP kinase signaling determines whether c-Jun N-terminal kinase promotes survival or apoptosis during glucose deprivation. Carcinogenesis 2009;30(3):529-37
95. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004;101(10):3329-35. (Pubitemid 38338195)
96. Lee M, Hwang JT, Lee HJ, et al. AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J Biol Chem 2003;278(41):39653-61. (Pubitemid 37248526)
97. Hwang JT, Lee M, Jung SN, et al. AMP-activated protein kinase activity is required for vanadate-induced hypoxia-inducible factor 1alpha expression in DU145 cells. Carcinogenesis 2004;25(12):2497-507 (Pubitemid 39625192)
98. Jung SN, Yang WK, Kim J, et al. Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis 2008;29(4):713-21 (Pubitemid 351494158)
99. Yun H, Lee M, Kim SS, et al. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 2005;280(11):9963-72 (Pubitemid 40395845)
100. Kim HS, Hwang JT, Yun H, et al. Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. J Biol Chem 2008;283(7):3731-42
101. MD BioAlpha Co., Ltd. Method of enhancing the effect of anti cancer drug by inhibition of the activity of AMPK. WO06004360; 2006
102. Iyengar RR, Judd AS, Zhao G, et al. Thienopyridones as AMPK activators for the treatment of diabetes and obesity. US20060287356; 2006
103. Goransson O, McBride A, Hawley SA, et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 2007;282(45):32549-60 (Pubitemid 350159310)
104. Sanders MJ, Ali ZS, Hegarty BD, et al. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 2007;282(45):32539-48 (Pubitemid 350159309)
105. Scott JW, van Denderen BJ, Jorgensen SB, et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem Biol 2008;15(11):1220-30
106. Merck Sante. Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them. EP1754483; 2007
107. Merck Patent Gmbh. Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators. WO2009124636 2009
108. Merck Patent Gmbh. Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators. WO2009135580 2009
109. Merrill GF, Kurth EJ, Hardie DG, et al. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 1997;273(6 Pt 1):E1107-12
110. Bergeron R, Russell RR III, Young LH, et al. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol 1999;276(5 Pt 1):E938-44 (Pubitemid 29249614)
111. Goodyear LJ. The exercise pill-too good to be true? N Engl J Med 2008;359(17):1842-4
112. Fabianowska-Majewska K, Duley JA, Simmonds HA. Effects of novel anti-viral adenosine analogues on the activity of S-adenosylhomocysteine hydrolase from human liver. Biochem Pharmacol 1994;48(5):897-903 (Pubitemid 24285167)
113. Longnus SL, Wambolt RB, Parsons HL, et al. 5-Aminoimidazole-4-carboxamide 1-beta -D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am J Physiol Regul Integr Comp Physiol 2003;284(4):R936-44 (Pubitemid 36406851)
114. Vincent MF, Marangos PJ, Gruber HE, et al. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 1991;40(10):1259-66
115. Moinet G, Marais D, Hallakou-Bozec S, et al. Use of AMPK-activating imidazole derivatives, preparation precess therefor and pharmaceutical compositions comprising them. US20090253764; 2009
116. Pang T, Zhang ZS, Gu M, et al. Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J Biol Chem 2008;283(23):16051-60.
117. Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Compounds used as mammalian cell AMP-activated protein kinase (AMPK) activators and their preparation methods and usages. WO2007062568; 2007
118. Lamia KA, Sachdeva UM, DiTacchio L, et al. AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science 2009;326(5951):437-40.
119. The Salk Institute for Biological Studies. Methods for modulating metabolic and circadian rhythms. WO2010108195; 2010
120. The Salk Institute for Biological Studies. Methods for modulating circadian rhythms. WO2010108179; 2010
121. McCullough LD, Zeng Z, Li H, et al. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J Biol Chem 2005;280(21):20493-502 (Pubitemid 40776749)
122. FASGEN, Llc. Novel method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase. WO05092068; 2007
123. Andersson U, Filipsson K, Abbott CR, et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 2004;279(13):12005-8 (Pubitemid 38445761)
124. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004;428(6982):569-74. (Pubitemid 38480541)
125. Kim EK, Miller I, Aja S, et al. C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem 2004;279(19):19970-6
126. Lopez M, Lage R, Saha AK, et al. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 2008;7(5):389-99 (Pubitemid 351618114)
127. Andersson U, Treebak JT, Nielsen JN, et al. Exercise in rats does not alter hypothalamic AMP-activated protein kinase activity. Biochem Biophys Res Commun 2005;329(2):719-25 (Pubitemid 40311802)
128. Kudo N, Gillespie JG, Kung L, et al. Characterization of 5AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1996;1301(1-2):67-75 (Pubitemid 26193063)
129. Xing Y, Musi N, Fujii N, et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem 2003;278(31):28372-7 (Pubitemid 36935737)
130. Russell RR III, Li J, Coven DL, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004;114(4):495-503 (Pubitemid 39572099)
131. Tian R, Musi N, DAgostino J, et al. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001;104(14):1664-9 (Pubitemid 32947531)
132. Osorio JC, Stanley WC, Linke A, et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002;106(5):606-12 (Pubitemid 34827712)
133. Olson RE. Myocardial metabolism in congestive heart failure. J Chronic Dis 1959;9(5):442-64
134. Wittels B, Spann JF Jr. Defective lipid metabolism in the failing heart. J Clin Invest 1968;47(8):1787-94
135. Recchia FA, McConnell PI, Bernstein RD, et al. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 1998;83(10):969-79 (Pubitemid 28520926)
136. Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. Circ Res 2007;100(4):474-88 (Pubitemid 46673257)
137. Birk JB, Wojtaszewski JF. Predominant alpha2/beta2/gamma3 AMPK activation during exercise in human skeletal muscle. J Physiol 2006;577(Pt 3):1021-32 (Pubitemid 44873663)
138. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9(5):1092-9
139. McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer 2008;8(3):205-11 (Pubitemid 351301840)
140. Leclerc I, Woltersdorf WW, da Silva Xavier G, et al. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 2004;286(6):E1023-31 (Pubitemid 38668827)
141. Riboulet-Chavey A, Diraison F, Siew LK, et al. Inhibition of AMP-activated protein kinase protects pancreatic beta-cells from cytokine-mediated apoptosis and CD8+ T-cell-induced cytotoxicity. Diabetes 2008;57(2):415-23
142. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009;8(1):88-96
143. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27(25):3576-86 (Pubitemid 351793803)
144. Kickstein E, Krauss S, Thornhill P, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA 2010;107(50):21830-5
145. Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010;11(5):390-401.
146. Guigas B, Bertrand L, Taleux N, et al. 5-Aminoimidazole-4-carboxamide-1- beta- D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes 2006;55(4):865-74 (Pubitemid 44100158)
147. Moreno D, Knecht E, Viollet B, et al. A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. FEBS Lett 2008;582(17):2650-4
148. Benziane B, Bjornholm M, Lantier L, et al. AMP-activated protein kinase activator A-769662 is an inhibitor of the Na(+)-K(+)-ATPase. Am J Physiol Cell Physiol 2009;297(6):C1554-66